DEXACEN-4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXACEN-4 (DEXACEN-4).
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5% |
| Half-life | 3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min) |
| Protein binding | 80-85%; primarily to albumin |
| Volume of Distribution | 0.3-0.5 L/kg; indicates distribution into total body water |
| Bioavailability | Oral: 60-70% (first-pass effect); IM: 90-95%; IV: 100% |
| Onset of Action | Oral: 1-2 hours; IM: 30-60 minutes; IV: 15-30 minutes |
| Duration of Action | Oral: 12-24 hours (sustained release); IM/IV: 6-12 hours; clinical effects persist for 24 hours post-dose due to active metabolites |
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; drug is minimally renally excreted. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of fluid retention and immunosuppression. |
| Pediatric use | 0.08-0.3 mg/kg/day orally or intravenously in divided doses every 6-12 hours; maximum 16 mg/day. |
| Geriatric use | Start at lower end of dosing range (e.g., 4 mg/day) due to increased risk of osteoporosis, hyperglycemia, and immunosuppression; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXACEN-4 (DEXACEN-4).
| Breastfeeding | Enters breast milk in low concentrations (M/P ratio ~0.3-0.6). Not associated with adverse effects in infants at maternal doses ≤20 mg/day prednisone equivalent. Monitor infant for growth and adrenal suppression with prolonged high-dose therapy. |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 1.3-3.3) and intrauterine growth restriction. Second/third trimester: Fetal adrenal suppression, oligohydramnios, and preterm delivery. Avoid systemic use unless maternal benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to dexamethasone or any component","Administration of live or live attenuated vaccines (relative)"]
| Precautions | ["Immunosuppression and increased risk of infection","Adrenal suppression with prolonged use","Osteoporosis with long-term use","Gastrointestinal perforation risk","Increased intraocular pressure/glaucoma","Cushing's syndrome with chronic use"] |
Loading safety data…
| Fetal Monitoring |
| Maternal blood pressure and glucose every 4-8 weeks; fetal growth ultrasound every 4-6 weeks; biophysical profile or nonstress test weekly if high-dose therapy (>20 mg/day prednisone equivalent) after 28 weeks. |
| Fertility Effects | May suppress gonadotropin release and disrupt menstrual cycles at high doses; reversible upon dose reduction or discontinuation. No documented negative effect on male fertility in therapeutic doses. |